Contemporary Reviews in Cardiovascular Medicine

Nitrate Therapy

New Aspects Concerning Molecular Action and Tolerance

Thomas Münzel, Andreas Daiber, Tommaso Gori
https://doi.org/10.1161/CIRCULATIONAHA.110.981407
Circulation. 2011;123:2132-2144
Originally published May 16, 2011

Jump to

Although the short-term vasodilatory properties of organic nitrates are potent and well known, a number of vascular and extravascular changes have been shown to compromise their hemodynamic effects on long-term administration. Among these changes, systemic phenomena such as neurohormonal activation and intravascular volume expansion1 as well as specific vascular changes such as increased vascular superoxide (O2·−) production,2 increased sensitivity to vasoconstrictors,3 and decreased responsiveness to nitric oxide (NO) donors4,5 have long been identified as playing a role. Several hypotheses have been proposed to explain these abnormalities, and over the last 15 years, our groups have focused on the concept that an inappropriate production of reactive oxygen species (ROS), an impairment in the scavenging of these mediators (Figure 1), or both might have a crucial mechanistic importance in all these modifications.6,7 Independently of the role of ROS in tolerance, the possibility that nitrate-induced oxidative stress might affect patients' prognosis has important implications, and the observation that long-term therapy with most of the drugs in this class causes endothelial dysfunction, the prognostic significance of which is well accepted in patients with coronary artery disease, hypertension, and heart failure,8 should not be taken as an academic curiosity.

Figure 1.
Figure 1.

Free radical biochemistry. The radical nitric oxide reacts with superoxide to form the highly reactive intermediate peroxynitrite. Superoxide is dismutated by superoxide dismutase (SOD), leading to the formation of hydrogen peroxide (H2O2) and molecular oxygen (O2).

Beyond these as-yet insufficiently investigated prognostic implications, recognition of the role of ROS suggests that a number of interventions thought to interfere with the vascular redox balance might also retard or prevent the development of nitrate tolerance and nitrate-induced side effects. Evidence that therapy with angiotensin-converting enzyme (ACE) inhibitors, angiotensin-1 receptor blockers, certain β-blockers, statins, and vitamins such as folic acid or vitamin C beneficially influence nitrate tolerance and glyceryl trinitrate (GTN)–induced endothelial dysfunction suggests that nitrate therapy might have profoundly different implications since these therapies have become diffusely available. In addition, the recognition of important differences in the mechanisms triggered by different nitrates should also be attributed clinical relevance, and evidence suggests that, rather than the generic nitrate tolerance, more specific expressions (GTN tolerance, isosorbide mononitrate [ISMN] tolerance, etc) should be used.9 This review summarizes the current concepts underlying tolerance and endothelial dysfunction in response to long-term therapy with different nitrates and addresses the question of whether the use of these drugs remains indicated despite these side effects.

The Hemodynamic Effects of Nitrates

Venous capacitance vessels, large and medium-sized coronary arteries, and collateral vessels are most sensitive to GTN, whereas coronary and peripheral arterioles with a diameter <100 μm are relatively more resistant. In the setting of stable angina, the preferential venodilatation induced by antiischemic doses of GTN results in venous pooling and preload reduction, yielding reduced left ventricular filling pressure and wall tension. As a result of these changes, myocardial workload and oxygen demand decrease (Figure 2). Beyond this effect, the clinical benefit of organic nitrates in the setting of acute coronary syndromes is thought to depend primarily on the dilation of epicardial coronaries and coronary collaterals, improving perfusion and oxygen delivery to subendocardial regions by increasing total coronary conductance. Furthermore, because the tone and caliber of myocardial resistance vessels are almost unaffected, coronary steal phenomena and reflex tachycardia are in general avoided. In summary, the mismatch between oxygen demand and supply in ischemic regions is rapidly relieved on short-term administration of organic nitrates.

Figure 2.
Figure 2.

Antianginal effects of acutely administered glyceryl trinitrate (GTN).

Through the same hemodynamic effects, organic nitrates also markedly improve left ventricular function in patients with congestive heart failure, decreasing right atrial pressure with a redistribution of blood from the central circulation into larger capacitance veins, a reduction in impedance to the left ventricle ejection owing to an increase in compliance of the arterial vasculature, and a reduction in the magnitude, frequency, and velocity of reflected waves in the arterial circulation. The resulting increase in cardiac output reduces left ventricular end-diastolic pressure and wall tension, thereby shifting the stroke-volume/left ventricular end-diastolic pressure relationship from a negative to a positive slope.

Antiaggregant Effects of Organic Nitrates

The effect of nitrates on platelet aggregation and fibrinolysis might also have clinical importance particularly in the setting of acute coronary syndromes in which vascular thrombosis determines low-flow ischemia. Glyceryl trinitrate reduces platelet aggregability ex vivo in healthy volunteers and to a lesser extent10,–,14 (a situation that parallels the reduced vasodilator potency of GTN observed in these clinical conditions15) in patients with insulin resistance, congestive heart failure, or coronary artery disease. Whether the antiaggregant effects of nitrates have an additional clinical impact on the therapy of coronary artery disease, particularly in light of the introduction and systematic use of targeted antiplatelet agents such as aspirin, thienopyridines, or glycoprotein IIb IIIa inhibitors, is unclear.

Mechanistic Insight

The principal mechanism underlying the hemodynamic effects of nitrates is believed to be the activation of the intracellular NO receptor enzyme soluble guanylyl cyclase, leading to increased bioavailability of cGMP and activation of cGMP-dependent protein kinases and/or cyclic nucleotide-gated ion channels (reviewed elsewhere16). The mechanism of GTN-induced inhibition of platelet aggregation is probably more complex in that it might involve both cGMP-dependent and -independent cGMP pathways.17,–,20 Whatever the mechanism, it appears to be (like the hemodynamic effects [see below]) redox dependent because antioxidants restored GTN responsiveness in heart failure and coronary artery disease patients.21 After the discovery of endogenous (endothelium-derived) NO and the recognition of its importance in controlling vascular homeostasis,22 the concept that nitrates may act as NO donors led to the speculation that these drugs might also be able to compensate for the compromised endothelial function typical of patients with cardiovascular disease. Evidence presented below suggests that this is not the case.

No Nitric Oxide From Glyceryl Trinitrate?

Evidence demonstrates that NO per se is not the mediator of the hemodynamic effects of GTN. Using spin trapping techniques, we found a striking dissociation between the vascular activity and NO donor properties23 for GTN compared with ISMN and isosorbide dinitrate (ISDN). Likewise, Nunez et al24 reported a similar discrepancy between the hemodynamic effects of GTN administration and NO release, suggesting that the action of GTN is unrelated to its bioconversion to NO. In another study, only suprapharmacological doses of short-term oral GTN evoked a measurable NO release.25 At the time of these observations, however, the mechanism of GTN biotransformation and its relationship with tolerance remained obscure. Evidence consonant with the hypothesis that the mediator is different among different nitrate molecules in this class was also provided by a recent study demonstrating that so-called NO donors such as GTN and pentaerythrityl tetranitrate (PETN) have different effects on myocardial gene expression.26 Treatment with GTN resulted in a larger expression of cardiotoxic genes and inhibition of the expression of cardioprotective proteins, whereas PETN treatment enhanced the expression of genes in the opposite direction. A possible explanation for this differential gene expression profiles in response to both compounds may be the release of different vasoactive molecules on bioactivation26 (Figure 3).

Figure 3.
Figure 3.

Effects of organic nitrates such as glyceryl trinitrate (GTN) and pentaerythrityl tetranitrate (PETN) on myocardial gene expression. Treatment with GTN significantly changed the expression of 532 genes; PETN treatment changed the expression of 1215 genes. Interestingly, only 68 genes were significantly changed by both compounds, raising doubt that a common vasoactive molecule, such as nitric oxide is released from both drugs. Adapted from Pautz et al.26

Aldehyde Dehydrogenase, the Enzyme That Metabolizes Alcohol, Also Bioactivates Glyceryl Trinitrate

Glyceryl trinitrate is metabolized by at least 2 different pathways (Figure 4). When administered in high doses (low-affinity pathway), GTN is metabolized by several enzymes, including glutathione-S-transferases, xanthine oxidoreductase, and the cytochrome P450. Beyond this low-affinity pathway, the relevance of which for clinically used dosages remains unclear, a high-affinity pathway was identified in 2002 by Chen et al,27 who suggested that the mitochondrial aldehyde dehydrogenase (ALDH-2), the enzyme responsible for the catabolism of alcohol, could also have a role in the bioactivation of GTN. Subsequent studies confirmed a marked attenuation of GTN-induced activation of the cGMP-dependent cascade and vasodilator potency after incubation with ALDH-2 inhibitors28,29 and extended these results to PETN; in contrast, ISMN and ISDN were unaffected by ALDH-2 inhibition (or genetic deletion).30,31

Figure 4.
Figure 4.

Proposed mechanisms underlying bioactivation of organic nitrates. Left, Characterization of the bioactivation of high-potency nitrates such as nitroglycerin (glyceryl trinitrate [GTN]), pentaerythrityl tetranitrate (PETN), and pentaerythrityl trinitrate (PETriN) by mitochondrial aldehyde dehydrogenase (ALDH-2) when used at low, clinically relevant concentrations (<1 μmol/L). The reductase activity converts the organic nitrates to nitrite and the denitrated metabolite (1,2-glyceryl dinitrate, PETriN, or its dinitrate, PEDN). In general, there are 3 proposed mechanisms including nitrogen oxide formed via a reduction of nitrite (NO2), nitric oxide, formed directly in response to interaction with the ALDH-2, and NO2, released from the mitochondria, may be reduced by the xanthine oxidase in the cytoplasm to form NO. Right, The bioactivation of low-potency nitrates such as isosorbide dinitrate (ISDN) and isosorbide-5-mononitrate (ISMN) but also GDN, PEDN, and their respective mononitrates GMN and PEMN by P450 enzyme(s) in the endoplasmic reticulum (ER), directly yielding nitric oxide. The latter mechanism also accounts for the high-potency nitrates when used at high concentrations (>1 μmol/L). Cyt Ox indicates cytochrome c oxidase.

The precise active metabolite formed during this process remains obscure; several hypotheses have been proposed. Whatever the nature of this chemical species, these findings found rapid human translation. For instance, incubation of human vessels with an ALDH-2 inhibitor recapitulated the abnormalities associated with the development of tolerance,32 (Figure 5) and a loss-of-function mutation of ALDH-2 particularly frequent in Eastern Asia and Eastern Europe was found to be associated with impaired GTN metabolism and reduced responsiveness to GTN.33

Figure 5.
Figure 5.

Effects of in vivo glyceryl trinitrate (GTN) treatment in patients undergoing bypass surgery on tolerance of mammary artery and vena saphena magna. A and B, in vivo treatment will lead to a marked degree of tolerance in the mammary artery and in vena saphena magna veins (blue lines). The shift to the right was comparable when the mammary artery and the vena saphena were treated in vitro with the aldehyde dehydrogenase (ALDH-2) inhibitor benomyl (green line). C, In vivo and in vitro treatment with GTN and benomyl resulted in comparable inhibition of the activity of ALDH-2 in arteries and veins. D, Long-term treatment with GTN leads to a downregulation of the GTN-bioactivating enzyme ALDH-2. Adapted from Hink et al,32 with permission of the publisher. Copyright © 2007, American College of Cardiology Foundation.

Nitrate Tolerance

The clinical introduction of organic nitrates at the end of the 19th century was soon followed by the observation that the hemodynamic and clinical effects of GTN, ISMN, and ISDN invariably wane upon continuous therapy. In the setting of coronary artery disease, nitrate tolerance has been demonstrated as the loss of effects on treadmill walking time and time of onset of angina. In congestive heart failure, it has been described as the loss of hemodynamic effect of the administered nitrate,34 and in hypertension, it is evident as the rapid loss of the hypotensive effects of these drugs. Rather controversial data have been reported for the antiplatelet effects of GTN. A study in dogs showed that tolerance is associated with a paradoxical activation of platelets,35 and another report showed that prior exposure to GTN, even in very low doses, induces tolerance to the antiaggregatory effects of the drug.36 In contrast, other studies in both rats and humans have shown that platelet responsiveness is preserved despite hemodynamic tolerance.37,38 Another issue is the so-called nitrate resistance, ie, the reduced effectiveness of organic nitrates in the setting of cardiovascular disease, which limits nitrate effectiveness independently of prior nitrate use. For instance, McVeigh et al39 reported reduced hemodynamic effects in diabetic patients and (as mentioned above) that GTN-induced inhibition of platelet aggregability is blunted in patients with coronary artery disease or diabetes. To date, it remains unclear whether these different forms of reduced responsiveness to nitrates share common mechanisms (eg, dysfunction of downstream NO signaling pathways) or should rather be considered 2 distinct entities. If the understanding of the mechanism of nitrate bioactivation has proved to be more complex than initially thought, the mechanism of the development of nitrate tolerance is likely even more complex in that it involves neurohormonal counterregulation, expansion of plasma volume (collectively classified as pseudotolerance), and intrinsic vascular processes, defined as true tolerance (the Table). Beyond the loss of the vasodilatory action of nitrates, a typical phenomenon associated with these changes is the worsening of anginal symptoms caused by the withdrawal of nitrate therapy, the so-called rebound effect.40

View this table:
Table.

Hypotheses Proposed to Explain the Development of Nitrate Tolerance

Nitrate Pseudotolerance

The vasodilation evoked by intravenous, oral, and transdermal nitrate therapy causes the release of catecholamines41 and plasma vasopressin41,42 and increases plasma renin activity41,42 and aldosterone levels.41,42 Such activation of neurohormonal vasoconstrictor forces has been demonstrated in patients with coronary artery disease, patients with heart failure,43 and healthy subjects.41 In line with these data, long-term continuous transdermal GTN therapy has been associated with altered autonomic neural function, including impaired baroreflex activity and prevalence of sympathetic to parasympathetic tone in the regulation of heart rate.44 In addition, in both animal and human studies, long-term therapy with organic nitrates was associated with increased sensitivity to receptor-dependent vasoconstrictors such as serotonin, phenylepherine, angiotensin II, and thromboxane.3,45

A marked increase in intravascular volume, secondary to the transvascular shift of fluid and/or to aldosterone-mediated salt and water retention, has also been observed in patients treated with GTN.41,42 Although these changes could attenuate the preload effect of GTN, evidence suggests that these mechanisms are not sufficient to fully explain the loss of nitrate effectiveness. For instance, there is a difference in the time frame of neurohormonal activation, plasma expansion, and development of tolerance42; furthermore, studies testing the effects of diuretics, β-blockers, or ACE inhibitors did not invariably reverse or prevent tolerance. Thus, although the possible prognostic implications of these changes need to be acknowledged, other mechanisms of tolerance and a hypothesis that explained all these changes had to be sought.

Does Oxidative Stress Account for Nitrate Tolerance and Cross-Tolerance?

In 1995, we proposed a new molecular mechanism for GTN tolerance and cross-tolerance. Critical to this concept was the evidence that the bioavailability of ROS in tolerant vessels amounted to about twice that in controls, and that this abnormality was corrected by the addition of liposomal superoxide dismutase, which dismutes O2·− to H2O2 and oxygen2 (Figure 1). Subsequently, we demonstrated that GTN treatment stimulates the vascular (and particularly endothelial) production of peroxynitrite, a highly reactive intermediate generated from the rapid, diffusion-limited reaction of NO with O2·−.32,46

Evidence of GTN-induced increased ROS production in humans was then obtained ex vivo in arterial segments and in blood or platelets taken from patients rendered tolerant to GTN.19,39,48,49 GTN tolerance was also associated with increased markers of free radical–induced lipid peroxidation such as cytotoxic aldehydes and isoprostanes50 and esterified 8-epi-PGF2α51 and with a mild reduction in the responsiveness to the NO donor sodium nitroprusside in healthy volunteers,4 which might also be compatible with ROS-mediated interference with NO signaling. From these findings, we proposed the existence of a unifying hypothesis that, founded on the concept of GTN-induced increased oxidative stress, could be compatible with the multiple different observations associated with long-term nitrate therapy.6,7,52

Mechanisms Underlying Tolerance: Impaired Biotransformation Versus Oxidative Stress Concept

Several concepts concerning the implications of the oxidative stress hypothesis of nitrate tolerance have been discussed intensively within the last decades. Importantly, the recognition of the role of a mitochondrial enzyme in the biotransformation of organic nitrates and of a role of mitochondrial oxidative stress in the development of tolerance provided a link between 2 only apparently separate hypotheses (reduced bioactivation versus ROS-mediated NO scavenging or ROS-mediated inactivation of NO signaling). This hypothesis is essentially based on the concept that the oxidation of thiol groups may cause inhibition of several enzymes (including ALDH-231 and guanylyl cyclase53) and therefore both reduced GTN biotransformation inefficient and NO signal transduction.28 In line with this, treatment of tolerant animals with mitochondria-targeted antioxidants completely prevented or reversed GTN tolerance,54 and heterozygous knockout of manganese-superoxide dismutase+/− markedly aggravated tolerance development in response to GTN.55

These data reconcile the bioactivation and oxidative stress hypotheses and provide an interesting clinical corollary of the original observations published by Needleman and Hunter56 showing that incubation with high concentrations of nitrates induced swelling of isolated cardiac mitochondria, stimulated oxygen consumption, and uncoupled oxidative phosphorylation, all data that are consistent with a mitochondrial source of nitrate-elicited ROS. Importantly, however, these considerations apply to GTN tolerance, but most likely not to ISMN or ISDN tolerance, because these drugs do not undergo mitochondrial metabolism.31

Regardless of the exact mechanism by which GTN stimulates mitochondrial ROS production (eg, premature release of partially reduced oxygen from mitochondrial complex I or III, initiation of lipid peroxidation, depolarization of mitochondrial membrane potential, mitochondrial swelling57), these observations support the idea that oxidative stress may directly impair GTN biotransformation, either by oxidative inhibition of ALDH-2 or by depletion of essential repair cofactors such as lipoic acid.58 Recent data obtained with purified ALDH-2 provide evidence that ALDH-2 could be a source of GTN-triggered ROS formation.59 The pathways leading to GTN tolerance in this hypothesis are summarized in Figure 6.

Figure 6.
Figure 6.

Molecular mechanisms of nitrate tolerance. Within 1 day of continuous low-dose glyceryl trinitrate (GTN) therapy, neurohormonal counterregulation consisting of increased catecholamine and vasopressin plasma levels, increased intravascular volume, and activation of the renin-angiotensin-aldosterone system (RAAS) reduces therapeutic efficacy (pseudotolerance). After 3 days, endothelial and smooth muscle dysfunction develops (vascular tolerance and cross-tolerance) by different mechanisms: (1) increased endothelial and smooth muscle superoxide formation from NADPH oxidase activation by protein kinase C (PKC) and from the mitochondria; (2) direct inhibition of nitric oxide synthase (NOS) activation by PKC; (3) uncoupling of endothelial NOS caused by limited BH4 availability resulting from peroxynitrite (ONOO−)-induced oxidation of BH4 and reduced expression of GTP-cyclohydrolase I (GTPCH-I); (4) vasoconstrictor supersensitivity caused by increased smooth muscle PKC activity; (5) impaired bioactivation of GTN caused by inhibition of aldehyde dehydrogenase (ALDH-2); (6) inhibition of smooth muscle soluble guanylate cyclase by superoxide and peroxynitrite; (7) increased inactivation of cGMP by phosphodiesterases (PDE); and (8) inhibition of prostacyclin synthase (PGI2-S) by peroxynitrite, leading to reduced PGI2 formation. For sake of clarity, tolerance-induced radical generation in endothelial mitochondria was omitted from the scheme.

The implications of ROS formation, however, are not limited to the mitochondrial matrix because ROS leaking into the cytoplasm have been demonstrated to activate a cross-talk with the vascular NADPH oxidase,60 resulting in further ROS production and in the formation of the highly reactive peroxynitrite. Although the role of each specific free radical is unclear, ROS and/or reactive nitrogen species such as peroxynitrite in turn may oxidize the endothelial NO synthase (eNOS) cofactor BH4; cause tyrosine nitration of the prostacyclin synthase, reducing endothelial prostacyclin formation; and directly inhibit the activity of the soluble guanylyl cyclase and/or other enzymes involved in NO signaling.

The impact of ROS on BH4 is particularly noteworthy. By oxidizing BH4, GTN may cause a phenomenon called eNOS uncoupling, whereby this enzyme, rather than NO, produces superoxide, which may further increase oxidative stress in vascular tissue in a positive feedback fashion.61 Although the existence of negative reports needs to be acknowledged,62 we recently demonstrated increased expression of an uncoupled NOS in an animal model of nitrate tolerance,63 an abnormality that was prevented by supplementation of BH4.64 It is also important to note that changes in ROS production such as an increase in NADPH oxidase activity and evidence for an uncoupled eNOS, all of which could be corrected by administration of vitamin C, have been observed not only in vascular tissue but also in platelets from GTN-treated volunteers.39 These observations are consistent with the hypothesis that nitrate-induced oxidative stress, with impairment of endogenous NO production, might underlie endothelial dysfunction (Figure 7).4,65,–,68

Figure 7.
Figure 7.

Organic nitrates cause endothelial dysfunction. Evidence for the development of endothelial dysfunction in response to nitroglycerin (glyceryl trinitrate [GTN]) in peripheral arterioles (A) and coronary arteries (B) and to isosorbide mononitrate (ISMN) peripheral arteries (C) was reported. Pentaerythrityl tetranitrate (PETN; D) caused no endothelial dysfunction in the brachial artery, whereas isosorbide dinitrate (ISDN) treatment did (E). Importantly, substances such as folic acid, which have been shown to cause recoupling of an uncoupled nitric oxide (NO) synthase, and the antioxidant vitamin C were able to improve endothelial dysfunction in patients treated with ISMN and GTN. The mechanisms underlying endothelial dysfunction in response to long-term ISDN therapy have not yet been established. FBF indicates forearm blood flow; C, control; LAD, left anterior descending artery; I/N, ratio of infused to noninfused arm; and Ach, acetylcholine. Adapted from Gori et al,4 Caramori et al,65 Thomas et al,66 Schnorbus et al,67 and Sekiya et al,68 with permission of the publisher. Copyright © 1998, 2001, 2007, American College of Cardiology Foundation.

Unresolved Issues

Although the above considerations have provided a new view of the pathophysiology of nitrate tolerance leading to a unifying hypothesis of the many abnormalities observed in this setting, it needs to be acknowledged that nitrate tolerance remains a complex phenomenon produced by several concurring mechanisms, many of which remain incompletely understood. In addition, a number of controversial issues remain. Although a ROS-dependent interference with NO signaling pathways is compatible with cross-tolerance to endothelium-dependent and -independent nitrovasodilators such as ISMN and ISDN, other hypotheses based on mechanisms that are independent of the oxidative stress concept (such as desensitization of the soluble guanylate cyclase via S-nitrosylation) have also been proposed.69 Notably, inactivation of ALDH-2 does not explain either tolerance to ISMN and ISDN or the existence of a certain degree of cross-tolerance between GTN and these drugs (the metabolism of which is ALDH-2 independent).25,70,71 In addition, induction of cGMP breakdown via phosphodiesterases is also a possible explanation for GTN tolerance and cross-tolerance.72

Furthermore, the role of ALDH-2 inactivation in GTN tolerance was challenged in an animal study that showed that treatment with inhibitors of ALDH-2 cyanamide or propionaldehyde causes a similar dose-dependent decrease in GTN-induced relaxation in both tolerant and nontolerant aorta.73 In addition, despite showing a markedly reduced GTN-induced vasodilation in carriers of ALDH-2 polymorphisms and after ALDH-2 inhibition, human studies suggested that this enzyme accounts for only a half of the total bioactivation of GTN.33 Challenging the role of ROS-induced abnormalities, Sage et al49 reported an impaired biotransformation of GTN in venous tissue from patients treated with GTN but no cross-resistance to other NO donors and to a calcium ionophore; in this study, although the bioavailability of superoxide anion was increased in arterial segments from the same patients, short-term exposure to oxidative stress did not change GTN responsiveness. Further emphasizing the complexity of the mechanisms underlying GTN tolerance, in another study, folic acid preserved arterial, but not venous, responsiveness to sublingual GTN,74 suggesting the existence of different mechanisms across different vascular beds. Finally, the relative importance of the different free radical species (superoxide anion, hydroxyl radical, peroxynitrite, etc) remains unclear.

Clinical Implications

Therapy With Organic Nitrates Impairs Endothelial Function

A number of lines of evidence show that therapy with most organic nitrates in clinically used doses impairs responsiveness to stimuli for the release of endothelium-derived NO (Figure 7). This phenomenon, also known as endothelial dysfunction, has been observed in animal studies and in humans during prolonged GTN, ISMN, and ISDN therapy. In large coronary arteries, continuous treatment (5 days) with transdermal GTN leads to enhanced acetylcholine-induced paradoxical constriction instead of endothelium-dependent vasodilation.65,75 Evidence of impaired responses to acetylcholine was found in arteries removed from patients undergoing nitrate therapy at the time of bypass surgery,48 and continuous treatment with transdermal GTN resulted in a marked reduction of acetylcholine-induced increases in forearm blood flow in healthy volunteers treated with GTN for 6 days.4 Emphasizing the existence of specific abnormalities at the level of the eNOS, the vasoconstriction elicited in control subjects by the infusion of a specific inhibitor was significantly blunted after GTN therapy. Finally, in the lowest concentration, the eNOS inhibitor even caused a paradoxical dilation, which was interpreted as human in vivo evidence of GTN-induced eNOS uncoupling (and resulting paradoxical production of a vasoconstrictor). In line with this finding, GTN-induced endothelial dysfunction was prevented by folic acid, a compound that facilitates recoupling of eNOS.76

Most important, endothelial dysfunction is not limited to treatment with GTN in tolerance-inducing doses; it was also demonstrated after treatment with intermittent dosing of ISMN.66 Evidence of endothelial dysfunction has been shown on withdrawal of nitrate therapy,65,75,77 an observation that might suggest a role of impaired endothelial homeostasis in the rebound phenomenon. So far, the mechanisms (and the enzymatic superoxide source) involved in the increased oxidative stress in response to long-term ISMN treatment remain obscure. No endothelial dysfunction was observed in response to long-term PETN treatment, which is likely due to the upregulation of the antioxidant enzyme hemeoxygenase-1 (HO-I).67 Compared with equipotent dosages of nicorandil, ISDN (40 mg/d) treatment for 3 months was associated with a reduction in endothelium-dependent flow-mediated dilation,68 an effect similar to that observed with GTN (Figure 7).

In summary, evidence that chronic nitrate treatment causes endothelial dysfunction is now substantial. Given its role as a predictor of adverse long-term outcome in patients with coronary artery disease,78 it will be important to investigate in the future whether chronic therapy with organic nitrates modifies patients' prognosis.

Are All Nitrates Homogeneous in the Induction of Tolerance and Endothelial Dysfunction

It is well accepted that tolerance develops in response to long-term continuous administration of ISDN and ISMN (studies before 1990 are reviewed elsewhere79); however, there is also evidence that tolerance might not be a class effect. In contrast to other long-acting nitrates, studies in healthy volunteers showed a preserved vasodilator potency and an absence of oxidative stress and endothelial dysfunction50,80 during continuous PETN administration. In animals, PETN was even reported to prevent endothelial dysfunction and atherogenesis in animal models of atherosclerosis.81 The peculiar properties of this drug, including its capacity to induce the antioxidant defense protein heme oxygenase-1 and to increase the expression and production of ferritin, of the antioxidant molecule bilirubin, and of the vasodilator carbon monoxide82 have been investigated recently by our group83,84 (Figure 8).

Figure 8.
Figure 8.

Effects of manipulation of the activity and/or expression of the heme oxygenase-1 (HO-1) on the development of nitrate tolerance. Inhibition of HO-1 in pentaerythrityl tetranitrate (PETN)–treated animals caused tolerance and increased mitochondrial superoxide production; induction of HO-1 prevented tolerance in glyceryl trinitrate (GTN)–treated animals, mitochondrial vascular superoxide activity, and normalized the activity of the GTN-bioactivating enzyme aldehyde dehydrogenase (ALDH-2). Modified from Wenzel et al.84

Old and New Strategies to Prevent the Development of Tolerance and Cross-Tolerance

Nitrate-Free Interval

Tolerance of the hemodynamic effects of GTN can be avoided by the use of schedules that allow a regenerating daily interval of at least 12 hours.43 Although this strategy is intrinsically flawed by the fact that patients cannot receive a 24-hour treatment (and typically do not receive nitrate therapy in the early morning hours when the incidence of acute coronary syndromes is highest), it is effective in maintaining the hemodynamic effects of the nitrate. In addition, withdrawal of nitrate therapy results in the development of rebound ischemia, likely associated with the unrestrained effect of endothelial dysfunction and hypersensitivity to vasoconstrictors. The clinical correlate of this phenomenon (reviewed elsewhere85) is that, during the nitrate-free interval, the frequency of ischemic episodes is significantly increased, compensating for the benefit of nitrates. In patients with stable angina, Freedman et al86 have shown an increase in the duration of silent ischemia compared with patients treated with placebo, and other authors reported a decreased angina threshold after patch removal in both small40 and larger multicenter trials.87 In the catheterization laboratory, acute nitrate withdrawal increased the coronary vasoconstrictor responses to acetylcholine, suggesting that the rebound phenomenon is secondary to an increased sensitivity to vasoconstrictors75; similar findings were reported in animal studies.48,88 Although it is unclear whether the rebound phenomenon occurs only at the vascular level,89 a nitrate-free interval cannot be taken as an acceptable solution.

Interestingly, clinical trials in patients failed to demonstrate the rebound phenomenon in patients with coronary artery disease treated with nitrates and concomitant treatment with ACE inhibitors90 or β-receptor blockers.91 This latter observation emphasizes how exposure to other therapies may alter the pharmacodynamic effects of nitrates and encourages the search for more novel strategies to prevent the development of nitrate side effects.

Sulfhydryl Group Donors

Following the Needleman and Johnson92 hypothesis that nitrate tolerance could be induced by depletion of the thiol groups necessary for the biotransformation of GTN, a number of animal and human studies have tested the effect of coadministration of sulfhydryl donors such as N-acetylcysteine43,93 and l-methionine94,95 with GTN. Almost 20 years later, there is general consensus that these molecules, likely through direct nonenzymatic interaction with GTN, potentiate its effect rather than preventing the development of tolerance. As described above, the identification of critical cysteinyl residues in the active site of ALDH-2 revived this hypothesis, suggesting that agents that “regenerate” the nitrate reductase activity of the ALDH-2 might find a role in the prevention of tolerance. Future research will need to develop clinically applicable thiol donors that may act by the same mechanism such as, for instance, lipoic acid.

Antioxidants

A corollary of the oxidative stress hypothesis of nitrate tolerance2 is that treatment with antioxidants may be successful in preventing this phenomenon. Studies published by Bassenge et al96,97 demonstrated that concomitant treatment with a variety of antioxidants preserves the sensitivity of the vasculature to organic nitrates in different animal experimental models. The translation of these results to clinical practice is limited by the fact that oral administration of an effective antioxidant has proved to be more complicated than initially thought.98 This failure appears to mirror the lack of efficacy of oral antioxidants in improving cardiovascular prognosis.99 Although intra-arterial administration of high-dose vitamin C consistently appears to reverse tolerance,66 a positive effect of oral formulations appears to be much less reproducible.98 The development of more potent, more targeted, and more bioavailable antioxidants, particularly targeted at the mitochondria will address these issues54 (Figure 9).

Figure 9.
Figure 9.

Effects of the mitochondria-targeted antioxidants (mito-quinone [MQ] and a glutathione ester [GSH]) on tolerance development (left) and superoxide production (right). MQ completely prevented tolerance in isolated organ chamber experiments as indicated by the normalization of the glyceryl trinitrate (GTN) dose-response relationship. In addition, the GTN-induced increase in production of reactive oxygen species (ROS) in cultured endothelial cells was completely prevented by MQ or GSH ester treatment and by depletion of mitochondrial proteins. CTR indicates control; p0, cells without mitochondria. Adapted from Esplugues et al,54 with permission of the publisher. Copyright © 2006, Lippincott Williams & Wilkins.

Angiotensin-Converting Enzyme Inhibitors and Angiotensin-1 Receptor Blockers

The counterregulatory mechanisms triggered by nitrate therapy may offset the direct vasodilatory effects of GTN and, together with sodium and water retention, may coincide to counterbalance the hemodynamic benefit of these drug. Importantly, the critical role of the renin-angiotensin axis is confirmed by the evidence that ACE inhibitors prevent the development of tolerance in animal100 and human studies.101

In line with the role of ACE inhibitors, nitrate tolerance and nitrate-induced oxidative stress in animal models are markedly attenuated at the level of both conductance and resistance vessels during concomitant administration of angiotensin-1 receptor blockers.102 Although it is unclear whether this also applies to humans,103 given the systematic use of ACE inhibitors (eg, in the setting of congestive heart failure), these studies reinforce the concept that nitrate therapy in the modern clinical setting might have totally different implications than what is observed in experimental models (and in former clinical practice).

Hydralazine

A favorable interaction between hydralazine and nitrates has been demonstrated in the Veterans Heart Failure Trial (V-HeFT) and in the African-American Heart Failure Trial (A-HeFT).104,105 This particular combination has been shown to have beneficial effects on left ventricular function and exercise capacity; most important, it has been shown to improve survival in large studies in patients with severe heart failure. Although prevention of tolerance is only one of the possible mechanisms to explain the benefit associated with this association, hydralazine has also been shown to restore GTN responsiveness in both experimental animals and humans with congestive heart failure106 (negative studies also exist107). Hydralazine is a strong arteriolar dilator, and although (when given alone) it stimulates reflex increases in vasoconstrictor stimuli, including circulating catecholamines and plasma renin activity, in animal studies, when combined with GTN, it completely prevented the increase in vascular superoxide production and tolerance.108,109 In vitro, hydralazine also has been shown to possess powerful peroxynitrite-quenching properties.108 It remains to be tested whether coadministration of this vasodilator might be indicated in patients receiving nitrates for indications other than heart failure.

Carvedilol

Third-generation β-blockers such as carvedilol possess additional endotheliotropic properties that might modify the development of tolerance. In animal models, the effect of antioxidant carvedilol in preventing tolerance was similar to that of intravenous vitamin C infusions.110 In studies in patients with arterial hypertension or congestive heart failure, carvedilol, but not atenolol, metoprolol, or doxazosin, preserved the vasodilatory effect of GTN in resistance arteries despite the administration of transdermal GTN in tolerance-inducing doses.111

Statins

Therapy with statins has been associated with a number of benefits that are independent of their effect on lipid levels. In animal studies, both pravastatin and atorvastatin prevented nitrate tolerance and vascular superoxide formation induced by subcutaneous GTN injections,112 an effect that was associated with increased basal cGMP levels and was abolished when the rats received an inhibitor of the eNOS concomitantly with GTN. These animal data were confirmed by a recent human study showing that administration of atorvastatin prevents both GTN-induced endothelial dysfunction and tolerance in healthy volunteers.113 Finally, therapy with statins also appears to improve platelet reactivity to GTN in patients with stable or unstable coronary syndromes.13

Summary and Clinical Implications

Prolonged exposure to organic nitrates induces tolerance and endothelial dysfunction in patients with cardiovascular disease65,76 and healthy volunteers.4 Although these phenomena have previously been interpreted as the simple loss of a beneficial effect, their prognostic implications remain unexplored, and a recent meta-analysis indicates that long-term therapy with organic nitrates such as ISDN and ISMN may worsen the prognosis of patients with ischemic heart disease.114

Complicating the interpretation of these observations, however, clear differences between organic nitrates have been recognized. An interesting example is probably the tetranitrate PETN, which appears to be devoid of tolerance, endothelial dysfunction, and oxidative stress while maintaining the preconditioning-like protective properties.9 On the basis of current knowledge, organic nitrates can no longer be considered a group of compounds with homogeneous properties and effects but rather a group of substances releasing differing bioactive molecules that lead to distinct implications with respect to tolerance, oxidative stress, and endothelial dysfunction. In line with this, the mechanism of tolerance probably differs significantly across compounds in this class and across vascular beds. Furthermore, we should acknowledge that the implications of GTN-induced stimulation of vascular (mitochondrial) reactive oxygen species are not exclusively negative; a GTN-triggered short-term mitochondrial production of ROS paradoxically plays a role in the preconditioning-mimetic effects of nitrates,115,116 which have been proposed to explain the reduced incidence of ST-elevation myocardial infarctions (and improved prognosis) observed in patients undergoing nitrate therapy in the Global Registry of Acute Coronary Events (GRACE) trial.117 Finally, drugs such as ACE inhibitors, angiotensin-1 receptor blockers, l-arginine, BH4, folic acid, and ascorbate restore the sensitivity to GTN and profoundly modify the vascular effects of nitrates.

In summary, nitrate tolerance (or rather GTN, ISMN, and ISDN tolerance) is a complex phenomenon caused by abnormalities in the biotransformation and signal transduction of nitrates and by activation of counterregulatory mechanisms. Although the issue of the clinical implications of nitrate therapy has not been addressed by randomized clinical trials, it is clear that the pharmacology of organic nitrates is also more complex, interesting, and elusive than previously thought.

Sources of Funding

These studies were supported in part by a grant by the Federal Ministry of Education and Research (BMBF 01EO1003), by the Deutsche Forschungsgemeinschaft, and by vascular biology grants from ACTAVIS.

Disclosures

Drs Münzel and Gori have received honoraria from ACTAVIS for lectures. Dr Daiber has received honoraria and a vascular biology grant from ACTAVIS.

Acknowledgments

We greatly appreciate the technical assistance of Margot Neuser.

References

  1. 1.↵
    1. Parker JO,
    2. Parker JD
    . Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am J Cardiol.1992;70:93B–97B.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Munzel T,
    2. Sayegh H,
    3. Freeman BA,
    4. Tarpey MM,
    5. Harrison DG
    . Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187–194.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Munzel T,
    2. Giaid A,
    3. Kurz S,
    4. Stewart DJ,
    5. Harrison DG
    . Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A. 1995;92:5244–5248.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Gori T,
    2. Mak SS,
    3. Kelly S,
    4. Parker JD
    . Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol. 2001;38:1096–1101.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Mayer B,
    2. Kleschyov AL,
    3. Stessel H,
    4. Russwurm M,
    5. Munzel T,
    6. Koesling D,
    7. Schmidt K
    . Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation. Mol Pharmacol. 2009;75:886–891.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Gori T,
    2. Parker JD
    . Nitrate tolerance: a unifying hypothesis. Circulation. 2002;106:2510–2513.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Munzel T,
    2. Daiber A,
    3. Mulsch A
    . Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618–628.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Munzel T,
    2. Sinning C,
    3. Post F,
    4. Warnholtz A,
    5. Schulz E
    . Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40:180–196.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Gori T,
    2. Daiber A
    . Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate. Am J Cardiovasc Drugs. 2009;9:7–15.
    OpenUrlPubMed
  10. 10.↵
    1. Chirkov YY,
    2. Naujalis JI,
    3. Barber S,
    4. Sage RE,
    5. Gove DW,
    6. Brealey JK,
    7. Horowitz JD
    . Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects. Am J Cardiol. 1992;70:802–806.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Chirkov YY,
    2. Horowitz JD
    . N-acetylcysteine potentiates nitroglycerin-induced reversal of platelet aggregation. J Cardiovasc Pharmacol. 1996;28:375–380.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Anfossi G,
    2. Mularoni EM,
    3. Burzacca S,
    4. Ponziani MC,
    5. Massucco P,
    6. Mattiello L,
    7. Cavalot F,
    8. Trovati M
    . Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 1998;21:121–126.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Chirkov YY,
    2. Holmes AS,
    3. Willoughby SR,
    4. Stewart S,
    5. Wuttke RD,
    6. Sage PR,
    7. Horowitz JD
    . Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol. 2001;37:1851–1857.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Anderson RA,
    2. Ellis GR,
    3. Evans LM,
    4. Morris K,
    5. Chirkov YY,
    6. Horowitz JD,
    7. Jackson SK,
    8. Rees A,
    9. Lewis MJ,
    10. Frenneaux MP
    . Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes. Diab Vasc Dis Res. 2005;2:88–93.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. McVeigh G,
    2. Brennan G,
    3. Hayes R,
    4. Johnston D
    . Primary nitrate tolerance in diabetes mellitus. Diabetologia. 1994;37:115–117.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Munzel T,
    2. Feil R,
    3. Mulsch A,
    4. Lohmann SM,
    5. Hofmann F,
    6. Walter U
    . Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase [corrected]. Circulation. 2003;108:2172–2183.
    OpenUrlFREE Full Text
  17. 17.↵
    1. Aoki H,
    2. Inoue M,
    3. Mizobe T,
    4. Harada M,
    5. Imai H,
    6. Kobayashi A
    . Platelet function is inhibited by nitric oxide liberation during nitroglycerin-induced hypotension anaesthesia. Br J Anaesth. 1997;79:476–481.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Booth BP,
    2. Tabrizi-Fard MA,
    3. Fung H
    . Calcitonin gene-related peptide-dependent vascular relaxation of rat aorta: an additional mechanism for nitroglycerin. Biochem Pharmacol. 2000;59:1603–1609.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Chirkov YY,
    2. Holmes AS,
    3. Chirkova LP,
    4. Horowitz JD
    . Nitrate resistance in platelets from patients with stable angina pectoris. Circulation. 1999;100:129–134.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Sogo N,
    2. Magid KS,
    3. Shaw CA,
    4. Webb DJ,
    5. Megson IL
    . Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun. 2000;279:412–419.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Ellis GR,
    2. Anderson RA,
    3. Chirkov YY,
    4. Morris-Thurgood J,
    5. Jackson SK,
    6. Lewis MJ,
    7. Horowitz JD,
    8. Frenneaux MP
    . Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol. 2001;37:564–570.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Palmer RM,
    2. Ferrige AG,
    3. Moncada S
    . Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–526.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Kleschyov AL,
    2. Oelze M,
    3. Daiber A,
    4. Huang Y,
    5. Mollnau H,
    6. Schulz E,
    7. Sydow K,
    8. Fichtlscherer B,
    9. Mulsch A,
    10. Munzel T
    . Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ Res. 2003;93:e104–e112.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Nunez C,
    2. Victor VM,
    3. Tur R,
    4. Alvarez-Barrientos A,
    5. Moncada S,
    6. Esplugues JV,
    7. D'Ocon P
    . Discrepancies between nitroglycerin and NO-releasing drugs on mitochondrial oxygen consumption, vasoactivity, and the release of NO. Circ Res. 2005;97:1063–1069.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Agvald P,
    2. Adding LC,
    3. Gustafsson LE,
    4. Persson MG
    . Nitric oxide generation, tachyphylaxis and cross-tachyphylaxis from nitrovasodilators in vivo. Eur J Pharmacol. 1999;385:137–145.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Pautz A,
    2. Rauschkolb P,
    3. Schmidt N,
    4. Art J,
    5. Oelze M,
    6. Wenzel P,
    7. Forstermann U,
    8. Daiber A,
    9. Kleinert H
    . Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects. Physiol Genomics. 2009;38:176–185.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Chen Z,
    2. Zhang J,
    3. Stamler JS
    . Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002;99:8306–8311.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Sydow K,
    2. Daiber A,
    3. Oelze M,
    4. Chen Z,
    5. August M,
    6. Wendt M,
    7. Ullrich V,
    8. Mulsch A,
    9. Schulz E,
    10. Keaney JF Jr.,
    11. Stamler JS,
    12. Munzel T
    . Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113:482–489.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Zhang J,
    2. Chen Z,
    3. Cobb FR,
    4. Stamler JS
    . Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. Circulation. 2004;110:750–755.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Chen Z,
    2. Foster MW,
    3. Zhang J,
    4. Mao L,
    5. Rockman HA,
    6. Kawamoto T,
    7. Kitagawa K,
    8. Nakayama KI,
    9. Hess DT,
    10. Stamler JS
    . An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2005;102:12159–12164.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Daiber A,
    2. Oelze M,
    3. Coldewey M,
    4. Bachschmid M,
    5. Wenzel P,
    6. Sydow K,
    7. Wendt M,
    8. Kleschyov AL,
    9. Stalleicken D,
    10. Ullrich V,
    11. Mulsch A,
    12. Munzel T
    . Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol. 2004;66:1372–1382.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Hink U,
    2. Daiber A,
    3. Kayhan N,
    4. Trischler J,
    5. Kraatz C,
    6. Oelze M,
    7. Mollnau H,
    8. Wenzel P,
    9. Vahl CF,
    10. Ho KK,
    11. Weiner H,
    12. Munzel T
    . Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels. J Am Coll Cardiol. 2007;50:2226–2232.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Mackenzie IS,
    2. Maki-Petaja KM,
    3. McEniery CM,
    4. Bao YP,
    5. Wallace SM,
    6. Cheriyan J,
    7. Monteith S,
    8. Brown MJ,
    9. Wilkinson IB
    . Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol. 2005;25:1891–1895.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Elkayam U,
    2. Kulick D,
    3. McIntosh N,
    4. Roth A,
    5. Hsueh W,
    6. Rahimtoola SH
    . Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation. 1987;76:577–584.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Fink B,
    2. Bassenge E
    . Association between vascular tolerance and platelet upregulation: comparison of nonintermittent administration of pentaerithrityltetranitrate and glyceryltrinitrate. J Cardiovasc Pharmacol. 2002;40:890–897.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Chirkov YY,
    2. Chirkova LP,
    3. Horowitz JD
    . Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol. 1997;80:128–131.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Booth BP,
    2. Jacob S,
    3. Bauer JA,
    4. Fung HL
    . Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Cardiovasc Pharmacol. 1996;28:432–438.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Holmes AS,
    2. Chirkov YY,
    3. Willoughby SR,
    4. Poropat S,
    5. Pereira J,
    6. Horowitz JD
    . Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. Br J Clin Pharmacol. 2005;60:355–363.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. McVeigh GE,
    2. Hamilton P,
    3. Wilson M,
    4. Hanratty CG,
    5. Leahey WJ,
    6. Devine AB,
    7. Morgan DG,
    8. Dixon LJ,
    9. McGrath LT
    . Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate. Circulation. 2002;106:208–213.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Parker JD,
    2. Parker AB,
    3. Farrell B,
    4. Parker JO
    . Intermittent transdermal nitroglycerin therapy: decreased anginal threshold during the nitrate-free interval. Circulation. 1995;91:973–978.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Parker JD,
    2. Farrell B,
    3. Fenton T,
    4. Cohanim M,
    5. Parker JO
    . Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation. 1991;84:2336–2345.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Munzel T,
    2. Heitzer T,
    3. Kurz S,
    4. Harrison DG,
    5. Luhman C,
    6. Pape L,
    7. Olschewski M,
    8. Just H
    . Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol. 1996;27:297–303.
    OpenUrlPubMed
  43. 43.↵
    1. Packer M,
    2. Lee WH,
    3. Kessler PD,
    4. Gottlieb SS,
    5. Medina N,
    6. Yushak M
    . Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799–804.
    OpenUrlPubMed
  44. 44.↵
    1. Gori T,
    2. Floras JS,
    3. Parker JD
    . Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol. 2002;40:2000–2005.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Heitzer T,
    2. Just H,
    3. Brockhoff C,
    4. Meinertz T,
    5. Olschewski M,
    6. Munzel T
    . Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol. 1998;31:83–88.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Warnholtz A,
    2. Mollnau H,
    3. Heitzer T,
    4. Kontush A,
    5. Moller-Bertram T,
    6. Lavall D,
    7. Giaid A,
    8. Beisiegel U,
    9. Marklund SL,
    10. Walter U,
    11. Meinertz T,
    12. Munzel T
    . Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol. 2002;40:1356–1363.
    OpenUrlCrossRefPubMed
  47. 47.
    1. Hink U,
    2. Oelze M,
    3. Kolb P,
    4. Bachschmid M,
    5. Zou MH,
    6. Daiber A,
    7. Mollnau H,
    8. August M,
    9. Baldus S,
    10. Tsilimingas N,
    11. Walter U,
    12. Ullrich V,
    13. Münzel T
    . Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol. 2003;42:1826–1834.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Schulz E,
    2. Tsilimingas N,
    3. Rinze R,
    4. Reiter B,
    5. Wendt M,
    6. Oelze M,
    7. Woelken-Weckmuller S,
    8. Walter U,
    9. Reichenspurner H,
    10. Meinertz T,
    11. Munzel T
    . Functional and biochemical analysis of endothelial (dys) function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation. 2002;105:1170–1175.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Sage PR,
    2. de la Lande IS,
    3. Stafford I,
    4. Bennett CL,
    5. Phillipov G,
    6. Stubberfield J,
    7. Horowitz JD
    . Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation. 2000;102:2810–2815.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Jurt U,
    2. Gori T,
    3. Ravandi A,
    4. Babaei S,
    5. Zeman P,
    6. Parker JD
    . Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol. 2001;38:854–859.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. McGrath LT,
    2. Dixon L,
    3. Morgan DR,
    4. McVeigh GE
    . Production of 8-epi prostaglandin F(2alpha) in human platelets during administration of organic nitrates. J Am Coll Cardiol. 2002;40:820–825.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Gori T,
    2. Parker JD
    . The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation. 2002;106:2404–2408.
    OpenUrlFREE Full Text
  53. 53.↵
    1. Mulsch A,
    2. Bauersachs J,
    3. Schafer A,
    4. Stasch JP,
    5. Kast R,
    6. Busse R
    . Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol. 1997;120:681–689.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Esplugues JV,
    2. Rocha M,
    3. Nunez C,
    4. Bosca I,
    5. Ibiza S,
    6. Herance JR,
    7. Ortega A,
    8. Serrador JM,
    9. D'Ocon P,
    10. Victor VM
    . Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res. 2006;99:1067–1075.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Daiber A,
    2. Oelze M,
    3. Sulyok S,
    4. Coldewey M,
    5. Schulz E,
    6. Treiber N,
    7. Hink U,
    8. Mulsch A,
    9. Scharffetter-Kochanek K,
    10. Munzel T
    . Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+/-): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol. 2005;68:579–588.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Needleman P,
    2. Hunter FE Jr.
    . Effects of organic nitrates on mitochondrial respiration and swelling: possible correlations with the mechanism of pharmacologic action. Mol Pharmacol. 1966;2:134–143.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Daiber A
    . Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta.2010;1797:897–906.
    OpenUrlPubMed
  58. 58.↵
    1. Wenzel P,
    2. Hink U,
    3. Oelze M,
    4. Schuppan S,
    5. Schaeuble K,
    6. Schildknecht S,
    7. Ho KK,
    8. Weiner H,
    9. Bachschmid M,
    10. Munzel T,
    11. Daiber A
    . Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity: implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem. 2007;282:792–799.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Wenzl MV,
    2. Beretta M,
    3. Gorren AC,
    4. Zeller A,
    5. Baral PK,
    6. Gruber K,
    7. Russwurm M,
    8. Koesling D,
    9. Schmidt K,
    10. Mayer B
    . Role of the general base Glu-268 in nitroglycerin bioactivation and superoxide formation by aldehyde dehydrogenase-2. J Biol Chem. 2009;284:19878–19886.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Wenzel P,
    2. Mollnau H,
    3. Oelze M,
    4. Schulz E,
    5. Wickramanayake JM,
    6. Muller J,
    7. Schuhmacher S,
    8. Hortmann M,
    9. Baldus S,
    10. Gori T,
    11. Brandes RP,
    12. Munzel T,
    13. Daiber A
    . First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal. 2008;10:1435–1447.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Schulz E,
    2. Jansen T,
    3. Wenzel P,
    4. Daiber A,
    5. Munzel T
    . Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal. 2008;10:1115–1126.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Schmidt K,
    2. Rehn M,
    3. Stessel H,
    4. Wolkart G,
    5. Mayer B
    . Evidence against tetrahydrobiopterin depletion of vascular tissue exposed to nitric oxide/superoxide or nitroglycerin. Free Radic Biol Med. 2010;48:145–152.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Munzel T,
    2. Li H,
    3. Mollnau H,
    4. Hink U,
    5. Matheis E,
    6. Hartmann M,
    7. Oelze M,
    8. Skatchkov M,
    9. Warnholtz A,
    10. Duncker L,
    11. Meinertz T,
    12. Forstermann U
    . Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res. 2000;86:E7–E12.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Gruhn N,
    2. Aldershvile J,
    3. Boesgaard S
    . Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol. 2001;416:245–249.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Caramori PR,
    2. Adelman AG,
    3. Azevedo ER,
    4. Newton GE,
    5. Parker AB,
    6. Parker JD
    . Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol. 1998;32:1969–1974.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Thomas GR,
    2. DiFabio JM,
    3. Gori T,
    4. Parker JD
    . Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol. 2007;49:1289–1295.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Schnorbus B,
    2. Schiewe R,
    3. Ostad MA,
    4. Medler C,
    5. Wachtlin D,
    6. Wenzel P,
    7. Daiber A,
    8. Munzel T,
    9. Warnholtz A
    . Effects of pentaerythritol tetranitrate on endothelial function in coronary artery disease: results of the PENTA study. Clin Res Cardiol. 2009;99:115–124.
    OpenUrlPubMed
  68. 68.↵
    1. Sekiya M,
    2. Sato M,
    3. Funada J,
    4. Ohtani T,
    5. Akutsu H,
    6. Watanabe K
    . Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol. 2005;46:63–67.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Sayed N,
    2. Kim DD,
    3. Fioramonti X,
    4. Iwahashi T,
    5. Duran WN,
    6. Beuve A
    . Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res. 2008;103:606–614.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Kukovetz WR,
    2. Holzmann S
    . Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries. J Cardiovasc Pharmacol. 1989; 14 (suppl 11): S40– S44.
    OpenUrlCrossRef
  71. 71.↵
    1. Dalal JJ,
    2. Parker JO
    . Nitrate cross-tolerance: effect of sublingual isosorbide dinitrate and nitroglycerin during sustained nitrate therapy. Am J Cardiol. 1984;54:286–288.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Kim D,
    2. Rybalkin SD,
    3. Pi X,
    4. Wang Y,
    5. Zhang C,
    6. Munzel T,
    7. Beavo JA,
    8. Berk BC,
    9. Yan C
    . Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation. 2001;104:2338–2343.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. DiFabio J,
    2. Ji Y,
    3. Vasiliou V,
    4. Thatcher GR,
    5. Bennett BM
    . Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol Pharmacol. 2003;64:1109–1116.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Gori T,
    2. Saunders L,
    3. Ahmed S,
    4. Parker JD
    . Effect of folic acid on nitrate tolerance in healthy volunteers: differences between arterial and venous circulation. J Cardiovasc Pharmacol. 2003;41:185–190.
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Azevedo ER,
    2. Schofield AM,
    3. Kelly S,
    4. Parker JD
    . Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol. 2001;37:505–509.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Gori T,
    2. Burstein JM,
    3. Ahmed S,
    4. Miner SE,
    5. Al-Hesayen A,
    6. Kelly S,
    7. Parker JD
    . Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation. 2001;104:1119–1123.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Gori T,
    2. Harvey P,
    3. Floras JS,
    4. Parker JD
    . Continuous therapy with nitroglycerin impairs endothelium-dependent vasodilation but does not cause tolerance in conductance arteries: a human in vivo study. J Cardiovasc Pharmacol. 2004;44:601–606.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Heitzer T,
    2. Schlinzig T,
    3. Krohn K,
    4. Meinertz T,
    5. Munzel T
    . Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673–2678.
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Ahlner J,
    2. Andersson RG,
    3. Torfgard K,
    4. Axelsson KL
    . Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev. 1991;43:351–423.
    OpenUrlPubMed
  80. 80.↵
    1. Gori T,
    2. Al-Hesayen A,
    3. Jolliffe C,
    4. Parker JD
    . Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers. Am J Cardiol. 2003;91:1392–1394.
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Hacker A,
    2. Muller S,
    3. Meyer W,
    4. Kojda G
    . The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br J Pharmacol. 2001;132:1707–1714.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Oberle S,
    2. Abate A,
    3. Grosser N,
    4. Hemmerle A,
    5. Vreman HJ,
    6. Dennery PA,
    7. Schneider HT,
    8. Stalleicken D,
    9. Schroder H
    . Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med (Maywood). 2003;228:529–534.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Wenzel P,
    2. Oelze M,
    3. Coldewey M,
    4. Hortmann M,
    5. Seeling A,
    6. Hink U,
    7. Mollnau H,
    8. Stalleicken D,
    9. Weiner H,
    10. Lehmann J,
    11. Li H,
    12. Forstermann U,
    13. Munzel T,
    14. Daiber A
    . Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol. 2007;27:1729–1735.
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    1. Schuhmacher S,
    2. Wenzel P,
    3. Schulz E,
    4. Oelze M,
    5. Mang C,
    6. Kamuf J,
    7. Gori T,
    8. Jansen T,
    9. Knorr M,
    10. Karbach S,
    11. Hortmann M,
    12. Mathner F,
    13. Bhatnagar A,
    14. Forstermann U,
    15. Li H,
    16. Munzel T,
    17. Daiber A
    . Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension. 2010;55:897–904.
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    1. Parker JD
    . Potential problems with intermittent nitrate therapy. Can J Cardiol. 1996; 12 (suppl C): 22C– 24C.
    OpenUrlPubMed
  86. 86.↵
    1. Freedman SB,
    2. Daxini BV,
    3. Noyce D,
    4. Kelly DT
    . Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period. J Am Coll Cardiol. 1995;25:349–355.
    OpenUrlCrossRefPubMed
  87. 87.↵
    1. Pepine CJ,
    2. Lopez LM,
    3. Bell DM,
    4. Handberg-Thurmond EM,
    5. Marks RG,
    6. McGorray S
    . Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the Second Transdermal Intermittent Dosing Evaluation Study (TIDES-II). J Am Coll Cardiol. 1997;30:955–961.
    OpenUrlCrossRefPubMed
  88. 88.↵
    1. Munzel T,
    2. Mollnau H,
    3. Hartmann M,
    4. Geiger C,
    5. Oelze M,
    6. Warnholtz A,
    7. Yehia AH,
    8. Forstermann U,
    9. Meinertz T
    . Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol. 2000;36:628–634.
    OpenUrlCrossRefPubMed
  89. 89.↵
    1. Hebert D,
    2. Lam JY
    . Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity. J Am Coll Cardiol. 2000;36:2311–2316.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Pasch T,
    2. Kleierl-Lindner C,
    3. Gotz H,
    4. Pichl J
    . Rebound hypertension after controlled hypotension and its prevention by captopril [in German]. Anaesthesist. 1986;35:66–72.
    OpenUrlPubMed
  91. 91.↵
    1. Ishikawa K,
    2. Yamamoto T,
    3. Kanamasa K,
    4. Hayashi T,
    5. Takenaka T,
    6. Kimura A,
    7. Miyataka M,
    8. Yabushita H,
    9. Kitayama K
    . Intermittent nitrate therapy for prior myocardial infarction does not induce rebound angina nor reduce cardiac events. Intern Med. 2000;39:1020–1026.
    OpenUrlCrossRefPubMed
  92. 92.↵
    1. Needleman P,
    2. Johnson EM Jr.
    . Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709–715.
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    1. Munzel T,
    2. Holtz J,
    3. Mulsch A,
    4. Stewart DJ,
    5. Bassenge E
    . Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation. 1989;79:188–197.
    OpenUrlAbstract/FREE Full Text
  94. 94.↵
    1. Levy WS,
    2. Katz RJ,
    3. Wasserman AG
    . Methionine restores the venodilative response to nitroglycerin after the development of tolerance. J Am Coll Cardiol. 1991;17:474–479.
    OpenUrlCrossRefPubMed
  95. 95.↵
    1. Munzel T,
    2. Mulsch A,
    3. Holtz J,
    4. Just H,
    5. Harrison DG,
    6. Bassenge E
    . Mechanisms of interaction between the sulfhydryl precursor l-methionine and glyceryl trinitrate. Circulation. 1992;86:995–1003.
    OpenUrlAbstract/FREE Full Text
  96. 96.↵
    1. Bassenge E,
    2. Fink N,
    3. Skatchkov M,
    4. Fink B
    . Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest. 1998;102:67–71.
    OpenUrlPubMed
  97. 97.↵
    1. Bassenge E,
    2. Fink B
    . Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Naunyn Schmiedebergs Arch Pharmacol. 1996;353:363–367.
    OpenUrlCrossRefPubMed
  98. 98.↵
    1. Milone SD,
    2. Pace-Asciak CR,
    3. Reynaud D,
    4. Azevedo ER,
    5. Newton GE,
    6. Parker JD
    . Biochemical, hemodynamic, and vascular evidence concerning the free radical hypothesis of nitrate tolerance. J Cardiovasc Pharmacol. 1999;33:685–690.
    OpenUrlCrossRefPubMed
  99. 99.↵
    1. Munzel T,
    2. Gori T,
    3. Bruno RM,
    4. Taddei S
    . Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J.2010;31:2741–2748.
    OpenUrlAbstract/FREE Full Text
  100. 100.↵
    1. Berkenboom G,
    2. Brekine D,
    3. Unger P,
    4. Grosfils K,
    5. Staroukine M,
    6. Fontaine J
    . Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Hypertension. 1995;26:738–743.
    OpenUrlAbstract/FREE Full Text
  101. 101.↵
    1. Mehra A,
    2. Ostrzega E,
    3. Shotan A,
    4. Johnson JV,
    5. Elkayam U
    . Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. Am J Cardiol. 1992;70:1310–1314.
    OpenUrlCrossRefPubMed
  102. 102.↵
    1. Frame MD,
    2. Fox RJ,
    3. Kim D,
    4. Mohan A,
    5. Berk BC,
    6. Yan C
    . Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II. Am J Physiol Heart Circ Physiol. 2002;282:H2377–H2385.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    1. Milone SD,
    2. Azevedo ER,
    3. Forster C,
    4. Parker JD
    . The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. J Cardiovasc Pharmacol. 1999;34:645–650.
    OpenUrlCrossRefPubMed
  104. 104.↵
    1. Cohn JN
    . Effect of vasodilator therapy on mortality in chronic congestive heart failure. Eur Heart J. 1988; 9 (suppl A): 171–173.
    OpenUrlAbstract/FREE Full Text
  105. 105.↵
    1. Cohn JN,
    2. Tam SW,
    3. Anand IS,
    4. Taylor AL,
    5. Sabolinski ML,
    6. Worcel M
    . Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail. 2007;13:331–339.
    OpenUrlCrossRefPubMed
  106. 106.↵
    1. Gogia H,
    2. Mehra A,
    3. Parikh S,
    4. Raman M,
    5. Ajit-Uppal J,
    6. Johnson JV,
    7. Elkayam U
    . Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575–1580.
    OpenUrlCrossRefPubMed
  107. 107.↵
    1. Parker JD,
    2. Parker AB,
    3. Farrell B,
    4. Parker JO
    . The effect of hydralazine on the development of tolerance to continuous nitroglycerin. J Pharmacol Exp Ther. 1997;280:866–875.
    OpenUrlAbstract/FREE Full Text
  108. 108.↵
    1. Daiber A,
    2. Oelze M,
    3. Coldewey M,
    4. Kaiser K,
    5. Huth C,
    6. Schildknecht S,
    7. Bachschmid M,
    8. Nazirisadeh Y,
    9. Ullrich V,
    10. Mulsch A,
    11. Munzel T,
    12. Tsilimingas N
    . Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865–1874.
    OpenUrlCrossRefPubMed
  109. 109.↵
    1. Müunzel T,
    2. Kurz S,
    3. Rajagopalan S,
    4. Thoenes M,
    5. Berrington WR,
    6. Thompson JA,
    7. Freeman BA,
    8. Harrison DG
    . Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465–1470.
    OpenUrlCrossRefPubMed
  110. 110.↵
    1. Fink B,
    2. Schwemmer M,
    3. Fink N,
    4. Bassenge E
    . Tolerance to nitrates with enhanced radical formation suppressed by carvedilol. J Cardiovasc Pharmacol. 1999;34:800–805.
    OpenUrlCrossRefPubMed
  111. 111.↵
    1. Watanabe H,
    2. Kakihana M,
    3. Ohtsuka S,
    4. Sugishita Y
    . Preventive effects of carvedilol on nitrate tolerance: a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol. 1998;32:1201–1206.
    OpenUrlCrossRefPubMed
  112. 112.↵
    1. Fontaine D,
    2. Otto A,
    3. Fontaine J,
    4. Berkenboom G
    . Prevention of nitrate tolerance by long-term treatment with statins. Cardiovasc Drugs Ther. 2003;17:123–128.
    OpenUrlCrossRefPubMed
  113. 113.↵
    1. Liuni A,
    2. Luca M,
    3. Uxa A,
    4. Mariani J,
    5. Gori T,
    6. Parker J
    . Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in humans in vivo. J Am Coll Cardiol. 2011 4; 57: 93–98.
    OpenUrlCrossRefPubMed
  114. 114.↵
    1. Nakamura Y,
    2. Moss AJ,
    3. Brown MW,
    4. Kinoshita M,
    5. Kawai C
    . Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies: Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999;138:577–585.
    OpenUrlCrossRefPubMed
  115. 115.↵
    1. Gori T,
    2. Parker JD
    . Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol. 2008;52:251–254.
    OpenUrlCrossRefPubMed
  116. 116.↵
    1. Gori T,
    2. Di Stolfo G,
    3. Sicuro S,
    4. Dragoni S,
    5. Lisi M,
    6. Forconi S,
    7. Parker JD
    . Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol. 2007;64:145–150.
    OpenUrlCrossRefPubMed
  117. 117.↵
    1. Ambrosio G,
    2. Del Pinto M,
    3. Tritto I,
    4. Agnelli G,
    5. Bentivoglio M,
    6. Zuchi C,
    7. Anderson FA,
    8. Gore JM,
    9. Lopez-Sendon J,
    10. Wyman A,
    11. Kennelly BM,
    12. Fox KA
    . Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. Eur Heart J. 31: 430– 438.
View Abstract

This Issue

Jump to

Article Tools

Share this Article

  • Email
  • Nitrate Therapy
    Thomas Münzel, Andreas Daiber and Tommaso Gori
    Circulation. 2011;123:2132-2144, originally published May 16, 2011
    https://doi.org/10.1161/CIRCULATIONAHA.110.981407
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects